The 9p21 polymorphism is linked with XXXX during acute phase of ST-segment elevation @entity583 .

@entity1 @entity1165 @entity2224 @entity955 @entity583 @entity943 @entity29766
UNASSIGNED: The aim of the study was to find whether @entity1 carrying polymorphic allele of the @entity29766 polymorphism from 9p21 locus have changed risk of @entity943 ( @entity955 , AF; sustained @entity1165 or @entity2224 , sVT/VF) during acute phase of @entity583 . Retrospective analysis of data collected prospectively from two independent centers was performed. The clinical data were pooled from two independent cardiac registries: (1) the Warsaw ACS genetic registry (STEMI and NSTEMI/UA @entity1 hospitalized in the years 2008-2011; only STEMI @entity1 were analyzed); (2) the Bialystok STEMI genetic registry (STEMI @entity1 hospitalized in years 2001-2005, who survived the first 48  h from hospital admission). Data regarding sVT/VF and AF within first 24  h were analyzed. The @entity1 were genotyped with @entity29766 polymorphism. 1083 @entity1 were included in the analysis; 62 (5.7  %) @entity1 had sVT/VF during acute phase and 78 (7.2  %) @entity1 had AF, 46 (4.2  %) @entity1 had new-onset AF. Minor allele frequency in all @entity1 with AF was significantly different from those without AF (0.40 vs 0.51, p  =  0.0096). When only new-onset AF was analyzed, the trend was the same, with significant protective effect in recessive model [OR 0.41 (95  % CI 0.17-0.97), p  =  0.025]. The effect was independent of age and GRACE score. No relationship was found between sVT/VF and @entity29766 . @entity1 with STEMI, who survived until hospitalization with polymorphic allele of 9p21 @entity29766 SNP have less AF during acute phase of STEMI. SNP @entity29766 is not linked with sVT/VF in acute phase of STEMI.
